Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Full enrollment reached in phase III trial of GMK cancer vaccine

Oct. 12, 1999

Phase I/II results support further development of Leuvectin

Oct. 8, 1999

NCI supports clinical development of StressGen's lead product

Oct. 7, 1999

York Medical to commence phase I/II trial of head and neck cancer therapy

Sep. 30, 1999

ImmunoGen exercises put option

Sep. 30, 1999

StressGen completes phase I trial of HspE7

Sep. 28, 1999

TriAb prolongs disease progression in breast cancer patients

Sep. 27, 1999

GM-CSF and MDX-H210 assessed in pilot trial in cancer patients

Sep. 24, 1999

FDA accepts IND for ImmunoGen's tumor-activated prodrug

Sep. 23, 1999

Kyowa Hakko begins clinical testing of MAb as melanoma Rx

Sep. 21, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...